Tagged with Switzerland

Switzerland Kari Sarvanto outlines his journey from leading PRIMEX to establishing CRAB, a preclinical oncology company focused on non-toxic cancer treatments. Sarvanto highlights his strategic leadership background, the innovative approach of targeting metabolic dysfunctions in cancer, and the promising progress of their lead drug, CRB091, particularly in treating aggressive cancers like…

Switzerland Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to bridge corporate and governmental interests. He explains his current focus on maintaining the strength of the US-Swiss business relationship, especially…

Switzerland Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European counterparts when it comes to healthcare digitalisation. Recent PharmaBoardroom interviewees weigh in on the country’s digital lag, its electronic patient…

Switzerland Daniel Weber of Boehringer Ingelheim Switzerland explores the company’s strategic initiatives and focus on innovation within the Swiss healthcare system. Weber emphasizes Boehringer Ingelheim’s long-term vision of transforming lives, its commitment to early diagnosis, and its expanding role in digital health.   Our purpose and strong pipeline are what truly…

Switzerland Incyte’s Jonathan Dickinson discusses the company’s mission to address unmet medical needs in oncology and autoimmune diseases while expanding its footprint across Europe. He highlights the strategic role of Incyte’s internal research, clinical trials, and recent product launches, along with their ambitions to double European revenues in the coming years.…

Switzerland Johnson & Johnson Innovative Medicine’s Max Pahlow discusses how the company’s commitment to innovation and patient care drives its success in Switzerland. He highlights the importance of advancing clinical trials, digitalization, and modernizing the pricing and reimbursement system to maintain Switzerland’s competitive edge in healthcare.   Switzerland isn’t a lucky…

Switzerland World-renowned oncologist Professor Susan Gasser outlines the innovative public-private partnership model in place at the ISREC Foundation at the AGORA Cancer Research Center in Lausanne. The unique model of ISREC/AGORA involves a reversal of the typical PPP structure, where the private foundation builds infrastructure and invites public institutions to collaborate,…

Switzerland Dr Frank Ruhli discusses the importance of attracting top talent and fostering academic freedom as key factors in achieving research excellence. Ruhli highlights his collaborative leadership style, significant achievements like establishing the One Health Institute, the value of international partnerships in advancing interdisciplinary medical research, and some of the key…

Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability.   Our vision is not just about…

Switzerland The Federal Office of Public Health (FOPH) is the body responsible for safeguarding public health in Switzerland, developing national health policies, and overseeing the Swiss healthcare system. In an exclusive conversation, FOPH Director Anne Lévy discusses the key challenges facing the Swiss healthcare system today and highlights potential solutions as…

Switzerland Thomas Wirth shares insights into Biomed’s strategic focus on the Swiss pharmaceutical market, offering comprehensive services from regulatory support to market access for RX and OTC products. He discusses Biomed’s commitment to long-term partnerships, technological advancements, and driving operational efficiency to stay competitive.   At Biomed, we prioritize delivering value…

Switzerland Hans Peter Borger of Spirig HealthCare discusses the company’s integration with the STADA Group and its focus on generics, consumer healthcare, and specialty markets, including Parkinson’s and rare diseases. He emphasises the importance of a growth mindset and a value-driven culture in navigating Switzerland’s regulatory landscape.   We are committed…